Performance of vitek 2 for antimicrobial susceptibility testing of acinetobacter baumannii, pseudomonas aeruginosa, and stenotrophomonas maltophilia with vitek 2 (2009 FDA) and CLSI M100S 26th edition breakpoints

April M. Bobenchik, Eszter Deak, Janet A. Hindler, Carmen L. Charlton, Romney M. Humphries

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

The performances of Vitek 2 AST-GN69 and AST-XN06 cards were compared to Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution (BMD) for 99 isolates of Pseudomonas aeruginosa, 26 Acinetobacter baumannii isolates, and 11 Stenotrophomonas maltophilia isolates. In total, 15 antimicrobials were evaluated, with 11 for P. Aeruginosa, 14 for A. baumannii, and 2 for S. maltophilia. Categorical agreement (CA) was assessed using both Vitek 2 breakpoints and 2016 CLSI M100S 26th edition breakpoints. The essential agreement values for P. Aeruginosa, A. baumannii, and S. maltophilia were 99.5%, 99.2%, and 100%, respectively. The CA values for P. Aeruginosa, A. baumannii, and S. maltophilia were 94.1%, 92.7%, and 95.5%, respectively, by the Vitek 2 breakpoints, and 93.4%, 92.3%, and 95.5%, respectively, by the CLSI breakpoints. Overall, the Vitek 2 performance was comparable to that of BMD using both Vitek 2 breakpoints and 2016 CLSI M100S 26th edition breakpoints. Improved performance was noted for the reformulated piperacillin-tazobactam and imipenem found on the AST-GN69 card, with no very major or major errors noted when using the CLSI breakpoints.

Original languageEnglish (US)
Pages (from-to)450-456
Number of pages7
JournalJournal of clinical microbiology
Volume55
Issue number2
DOIs
StatePublished - Feb 2017

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)

Cite this